Risk factors associated with the mucormycosis epidemic during the COVID-19 pandemic

被引:40
|
作者
Bhanuprasad, Kundakarla [1 ]
Manesh, Abi [1 ]
Devasagayam, Emily [1 ]
Varghese, Lalee [2 ]
Cherian, Lisa Mary [2 ]
Kurien, Regi [2 ]
Karthik, Rajiv [1 ]
Deodhar, Divya [1 ]
Vanjare, Harshad [3 ]
Peter, Jayanthi [4 ]
Michael, Joy S. [5 ]
Thomas, Meera [6 ]
Samuel, Prasanna [7 ]
Varghese, George M. [1 ]
机构
[1] Christian Med Coll & Hosp, Dept Infect Dis, Vellore, Tamil Nadu, India
[2] Christiartn Med Coll, Dept ENT & Rhinol 3, Vellore, Tamil Nadu, India
[3] Christian Med Coll & Hosp, Dept Radiodiag, Vellore, Tamil Nadu, India
[4] Christian Med Coll & Hosp, Dept Ophthalmol, Vellore, Tamil Nadu, India
[5] Christian Med Coll & Hosp, Dept Clin Microbiol, Vellore, Tamil Nadu, India
[6] Christian Med Coll & Hosp, Dept Pathol, Vellore, Tamil Nadu, India
[7] Christian Med Coll & Hosp, Dept Biostat, Vellore, Tamil Nadu, India
基金
英国惠康基金;
关键词
Mucormycosis; COVID-19 associated mucormycosis; Risk factors;
D O I
10.1016/j.ijid.2021.08.037
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
This study was performed to assess the risk factors driving the epidemic of coronavirus disease 2019 (COVID-19)-associated mucormycosis (COVID-Mucor) in India that has accompanied the COVID-19 pandemic, particularly during the second wave. Risk factors were analysed among 164 participants: 132 COVID-Mucor (cases) and 32 non-COVID-Mucor (controls). Data from a prospective cohort study of mucormycosis over a period of 1 year were used. Diabetes mellitus remained a significant risk factor in both groups (97%), while uncontrolled diabetes mellitus (odds ratio (OR) 4.6; P = 0.026) and newly detected diabetes (OR 3.3; P = 0.018) were more common among the cases. Most patients with COVID-Mucor had mild COVID-19. Steroid use, often unwarranted, was highly associated with COVID-Mucor after adjusting for other risk factors (OR 28.4; P = 0.001). Serum ferritin was significantly higher ( P = 0.041), while C reactive protein was not, suggesting that alterations in iron metabolism may predispose to COVID-Mucor. Oxygen was used only in a small minority of patients with COVID-Mucor. The in-hospital mortality in both groups was low. In conclusion, the Indian COVID-Mucor epidemic has likely been driven by a convergence of interlinked risk factors: uncontrolled diabetes mellitus, unwarranted steroid use, and perhaps COVID-19 itself. Appropriate steroid use in patients with severe COVID-19 and screening and optimal control of hyperglycaemia can prevent COVID-Mucor. (C) 2021 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )
引用
收藏
页码:267 / 270
页数:4
相关论文
共 50 条
  • [1] Risk Factors Associated with the Mucormycosis Epidemic During the COVID-19 Pandemic
    Bhanuprasad, K.
    Varghese, G. M.
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 116 : S55 - S56
  • [2] Mucormycosis and COVID-19 an epidemic in a pandemic?
    Banerjee, Indrajit
    Robinson, Jared
    Asim, Mohammad
    Sathian, Brijesh
    Banerjee, Indraneel
    [J]. NEPAL JOURNAL OF EPIDEMIOLOGY, 2021, 11 (02): : 1034 - 1039
  • [3] Mucormycosis Epidemic and Stroke in India During the COVID-19 Pandemic
    Padma Srivastava, M. V.
    Vishnu, Venugopalan Y.
    Pandit, Awadh Kishor
    [J]. STROKE, 2021, 52 (10) : E622 - E623
  • [4] Mucormycosis in COVID-19 pandemic: Risk factors and linkages
    Kumar, Manoj
    Sarma, Devojit Kumar
    Shubham, Swasti
    Kumawat, Manoj
    Verma, Vinod
    Singh, Birbal
    Nagpal, Ravinder
    Tiwari, R. R.
    [J]. CURRENT RESEARCH IN MICROBIAL SCIENCES, 2021, 2
  • [5] Mucormycosis: risk factors, diagnosis, treatments, and challenges during COVID-19 pandemic
    Ayushi Sharma
    Anjana Goel
    [J]. Folia Microbiologica, 2022, 67 : 363 - 387
  • [6] Mucormycosis: risk factors, diagnosis, treatments, and challenges during COVID-19 pandemic
    Sharma, Ayushi
    Goel, Anjana
    [J]. FOLIA MICROBIOLOGICA, 2022, 67 (03) : 363 - 387
  • [7] Mucormycosis and COVID-19: An epidemic within a pandemic in India
    Selarka, Lav
    Sharma, Suktara
    Saini, Dinesh
    Sharma, Sanjay
    Batra, Amit
    Waghmare, Vishal T.
    Dileep, Pratibha
    Patel, Sanket
    Shah, Monarch
    Parikh, Tejas
    Darji, Prakash
    Patel, Amit
    Goswami, Gaurav
    Shah, Anand
    Shah, Sandeep
    Lathiya, Harsh
    Shah, Moksha
    Sharma, Pranita
    Chopra, Surabhi
    Gupta, Ankur
    Jain, Neha
    Khan, Erum
    Sharma, Vijay K.
    Sharma, Arvind K.
    Chan, Amanda C. Y.
    Ong, Jonathan J. Y.
    [J]. MYCOSES, 2021, 64 (10) : 1253 - 1260
  • [8] An Epidemic of Mucormycosis Coinciding With the COVID-19 Pandemic in India
    MohanaSundaram, ArunSundar
    Thukani Sathanantham, Shanmugarajan
    Kulkarni, Abhijit
    Kulkarni, Shweta
    Chinchole, Vijay
    Patil, Bhushan
    Velayutham, Ravichandiran
    [J]. ASIA-PACIFIC JOURNAL OF PUBLIC HEALTH, 2022, 34 (2-3) : 304 - 305
  • [9] Epidemic of Mucormycosis in COVID-19 Pandemic: A Position Paper
    Kulkarni, Rahul
    Misra, Usha K.
    Meshram, Chandrashekhar
    Kochar, Dhanpat
    Modi, Manish
    Vishnu, Venugopalan Y.
    Garg, Ravindra K.
    Surya, Nirmal
    [J]. ANNALS OF INDIAN ACADEMY OF NEUROLOGY, 2022, 25 (01) : 7 - 10
  • [10] Surge of mucormycosis during the COVID-19 pandemic
    Dam, Paulami
    Cardoso, Marlon H.
    Mandal, Sukhendu
    Franco, Octavio L.
    Sagiroglu, Pinar
    Polat, Osman Ahmet
    Kokoglu, Kerem
    Mondal, Rittick
    Mandal, Amit Kumar
    Ocsoy, Ismail
    [J]. TRAVEL MEDICINE AND INFECTIOUS DISEASE, 2023, 52